| Jonathan Edward Lee, MD | |
|
2302 College Ave, Conway, AR 72034-6297 | |
| (501) 327-6665 | |
| (501) 730-0289 |
| Full Name | Jonathan Edward Lee |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 21 Years |
| Location | 2302 College Ave, Conway, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992924203 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | E-4718 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Conway Regional Health System | Conway, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Conway Anesthesiology Consultants, Pa | 6901796267 | 24 |
News Archive
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a Public Health Agency of Canada study assessing the effects of various interventions on the management of E. coli O157:H7 in Canadian beef came to a favourable conclusion with regard to pre-harvest vaccines such as the Company's Econiche cattle vaccine.
Breast cancer is the second leading cause of cancer death in women in the United States, with most deaths caused by the cancer spreading beyond the breast.
DSM, and Svelte® Medical Systems, Inc., a privately held company developing next generation endovascular therapies, today announced they have entered into a license and supply agreement granting Svelte the right to use DSM's proprietary bioerodible amino acid based drug carrier in the design of their All In One non-thrombogenic, non-inflammatory drug-eluting stent system.
The first long-term study shows that treatment with pyrimethamine and sulfadiazine (two anti-parasitic drugs) during the first year of life leads to a lasting reduction in brain and eye damage for children with congenital toxoplasmosis.
› Verified 5 days ago
| Entity Name | Conway Anesthesiology Consultants, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568423820 PECOS PAC ID: 6901796267 Enrollment ID: O20040318001545 |
News Archive
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a Public Health Agency of Canada study assessing the effects of various interventions on the management of E. coli O157:H7 in Canadian beef came to a favourable conclusion with regard to pre-harvest vaccines such as the Company's Econiche cattle vaccine.
Breast cancer is the second leading cause of cancer death in women in the United States, with most deaths caused by the cancer spreading beyond the breast.
DSM, and Svelte® Medical Systems, Inc., a privately held company developing next generation endovascular therapies, today announced they have entered into a license and supply agreement granting Svelte the right to use DSM's proprietary bioerodible amino acid based drug carrier in the design of their All In One non-thrombogenic, non-inflammatory drug-eluting stent system.
The first long-term study shows that treatment with pyrimethamine and sulfadiazine (two anti-parasitic drugs) during the first year of life leads to a lasting reduction in brain and eye damage for children with congenital toxoplasmosis.
› Verified 5 days ago
| Entity Name | Conway Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1730601451 PECOS PAC ID: 3173428414 Enrollment ID: O20171026001815 |
News Archive
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a Public Health Agency of Canada study assessing the effects of various interventions on the management of E. coli O157:H7 in Canadian beef came to a favourable conclusion with regard to pre-harvest vaccines such as the Company's Econiche cattle vaccine.
Breast cancer is the second leading cause of cancer death in women in the United States, with most deaths caused by the cancer spreading beyond the breast.
DSM, and Svelte® Medical Systems, Inc., a privately held company developing next generation endovascular therapies, today announced they have entered into a license and supply agreement granting Svelte the right to use DSM's proprietary bioerodible amino acid based drug carrier in the design of their All In One non-thrombogenic, non-inflammatory drug-eluting stent system.
The first long-term study shows that treatment with pyrimethamine and sulfadiazine (two anti-parasitic drugs) during the first year of life leads to a lasting reduction in brain and eye damage for children with congenital toxoplasmosis.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan Edward Lee, MD 2425 Prince St Ste 4, Conway, AR 72034-3701 Ph: (501) 327-6665 | Jonathan Edward Lee, MD 2302 College Ave, Conway, AR 72034-6297 Ph: (501) 327-6665 |
News Archive
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a Public Health Agency of Canada study assessing the effects of various interventions on the management of E. coli O157:H7 in Canadian beef came to a favourable conclusion with regard to pre-harvest vaccines such as the Company's Econiche cattle vaccine.
Breast cancer is the second leading cause of cancer death in women in the United States, with most deaths caused by the cancer spreading beyond the breast.
DSM, and Svelte® Medical Systems, Inc., a privately held company developing next generation endovascular therapies, today announced they have entered into a license and supply agreement granting Svelte the right to use DSM's proprietary bioerodible amino acid based drug carrier in the design of their All In One non-thrombogenic, non-inflammatory drug-eluting stent system.
The first long-term study shows that treatment with pyrimethamine and sulfadiazine (two anti-parasitic drugs) during the first year of life leads to a lasting reduction in brain and eye damage for children with congenital toxoplasmosis.
› Verified 5 days ago
Mr. David John Holmes, CRNA Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 525 Western Ave, Ste 201, Conway, AR 72034 Phone: 501-327-6665 Fax: 501-730-0289 | |
Carl Mark Clark, CRNA Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 525 Western Ave, Ste 201, Conway, AR 72034 Phone: 501-327-6665 Fax: 501-730-0289 | |
Mrs. Mary 'frankie' Sears, CRNA Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 525 Western Ave, Suite 201, Conway, AR 72034 Phone: 501-327-6665 Fax: 501-730-0289 | |
Mr. Charles Anthony Turchi, CRNA Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 525 Western Ave, Suite 201, Conway, AR 72034 Phone: 501-327-6665 Fax: 501-730-0289 | |
Jevin Allen Smith, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 525 Western Ave, Suite 201, Conway, AR 72034 Phone: 501-327-6665 Fax: 501-730-0289 | |
Mr. Mark N Meaux, CRNA Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 525 Western Ave, Suite 201, Conway, AR 72034 Phone: 501-327-6665 Fax: 501-730-0289 | |
Jennifer Evins Bishop, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2850 Prince St Ste 43, Conway, AR 72034 Phone: 501-327-6665 |